Selective late sodium current blockade with GS-458967 markedly reduces ischemia-induced atrial and ventricular repolarization alternans and ECG heterogeneity

Heart Rhythm

Volumn 11, Issue 10, 2014, Pages 1827-1835

  Bonatti, Rodolfo ^a,b   Silva, Ana Flavia Garcia ^a,b   Batatinha, Julio Americo Pereira ^a,b   Sobrado, Lucas F ^a,b   Machado, Ananda Dianni ^a,b   Varone, Bruno B ^a,b   Nearing, Bruce D ^a,c   Belardinelli, Luiz ^d   Verrier, Richard L ^a,b,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GILEAD SCIENCES   (United States)

Author keywords

Antiarrhythmicdrugs; Atrial fibrillation; Atrialischemia; Depolarization; Heterogeneity; Late Ina; Repolarization; Ventricular fibrillation; Ventricularischemia

Indexed keywords

ANTIARRHYTHMIC AGENT; FLECAINIDE; GS 458967; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG; 6-(4-(TRIFLUOROMETHOXY)PHENYL)-3-(TRIFLUOROMETHYL)(1,2,4)TRIAZOLO(4,3-A)PYRIDINE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY OCCLUSION; DRUG BLOOD LEVEL; ELECTROCARDIOGRAPHY; ELECTRODE CATHETER; HEART ATRIUM APPENDAGE; HEART ATRIUM ARRHYTHMIA; HEART DEPOLARIZATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; R WAVE; SODIUM CURRENT; T WAVE; YORKSHIRE PIG; ANIMAL; ATRIAL FIBRILLATION; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; HEART MUSCLE CONDUCTION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PIG; TIME FACTOR; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

ANIMALS; ATRIAL FIBRILLATION; CORONARY STENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; INJECTIONS, INTRAVENOUS; MALE; PYRIDINES; SODIUM CHANNEL BLOCKERS; SWINE; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; VENTRICULAR FIBRILLATION;

EID: 84921021755     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2014.06.017     Document Type: Article

References (37)

1. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, S.A. Murphy, A. Budaj, S. Varshavsky, A.A. Wolff, A. Skene, C.H. McCabe, and E. Braunwald Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
2. B.M. Scirica, D.A. Morrow, H. Hod, S.A. Murphy, L. Belardinelli, C.M. Hedgepeth, P. Molhoek, F.W. Verheugt, B.J. Gersh, C.H. McCabe, and E. Braunwald Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial Circulation 116 2007 1647 1652
3. C. Antzelevitch, A. Burashnikov, S. Sicouri, and L. Belardinelli Electrophysiologic basis for the antiarrhythmic actions of ranolazine Heart Rhythm 8 2011 1281 1290
4. L.S. Maier A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine J Cardiovasc Pharmacol 54 2009 279 286
5. L. Belardinelli, G. Liu, and C. Smith-Maxwell A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias J Pharmacol Exp Ther 344 2013 23 32
6. T. Nieminen, D.Y. Nanbu, I.P. Datti, G.R. Vaz, C.A.M. Tavares, J.R.M. Pegler, B.D. Nearing, L. Belardinelli, and R.L. Verrier Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model Heart Rhythm 8 2011 608 614
7. R.L. Verrier, V.P.F. Pagotto, A.F. Kanas, M.F. Sobrado, B.D. Nearing, D. Zeng, and L. Belardinelli Low doses of ranolazine and dronedarone in combination exert potent protection against atrial fibrillation and vulnerability to ventricular arrhythmias during acute myocardial ischemia Heart Rhythm 10 2013 121 127
8. M. Alasady, W.P. Abhayaratna, D.P. Leong, H.S. Lim, H.S. Abed, A.G. Brooks, S. Mattchoss, K.C. Roberts-Thomson, M.I. Worthley, D.P. Chew, and P. Sanders Coronary artery disease affecting the atrial branches is an independent determinant of atrial fibrillation after myocardial infarction Heart Rhythm 8 2011 955 960
9. R.L. Verrier, T. Klingenheben, M. Malik, N. El-Sherif, D. Exner, S. Hohnloser, T. Ikeda, J.P. Martinez, S. Narayan, T. Nieminen, and D.S. Rosenbaum Microvolt T-wave alternans: physiologic basis, methods of measurement, and clinical utility. Consensus guideline by the International Society for Holter and Noninvasive Electrocardiology J Am Coll Cardiol 44 2011 1309 1324
10. B.D. Nearing, G.A. Wellenius, M.A. Mittleman, M.E. Josephson, A.J. Burger, and R.L. Verrier Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure Circ Arrhythm Electrophysiol 5 2012 84 90
11. R.L. Verrier, and T. Ikeda Ambulatory ECG-based T-wave alternans monitoring for risk assessment and guiding medical therapy: mechanisms and clinical applications Prog Cardiovasc Dis 56 2013 172 185
12. B.D. Nearing, and R.L. Verrier Modified moving average method for T-wave alternans analysis with high accuracy to predict ventricular fibrillation J Appl Physiol 92 2002 541 549
13. B.D. Nearing, and R.L. Verrier Tracking heightened cardiac electrical instability by computing interlead heterogeneity of T-wave morphology J Appl Physiol 95 2003 2265 2272
14. S.X. Zhao, L.M. Lee, B.D. Nearing, V.O. Busso, K.F. Kwaku, and R.L. Verrier Suppression of calcium-induced repolarization heterogeneity as a mechanism of nitroglycerin's antiarrhythmic action J Cardiovasc Pharmacol 48 2006 22 29
15. L. Rivard, H. Sinno, A. Shiroshita-Takeshita, G. Schram, T.-K. Leung, and S. Nattel The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy Cardiovasc Res 74 2007 104 113
16. R.E. Patterson, and E.S. Kirk Analysis of coronary collateral structure, function, and ischemic border zones in pigs Am J Physiol 244 1983 H23 H31
17. K. Kumar, K. Nguyen, S. Waxman, B.D. Nearing, G. Wellenius, S.X. Zhao, and R.L. Verrier Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart J Am Coll Cardiol 41 2003 1831 1837
18. V. Fuster, L.E. Rydén, and D.S. Cannom 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
19. V.A. Maltsev, and A.I. Undrovinas A multi-modal composition of the late Na1 current in human ventricular cardiomyocytes Cardiovasc Res 69 2006 116 127
20. A. Zaza, L. Belardinelli, and J.C. Shryock Pathophysiology and pharmacology of the cardiac "late sodium current." Pharmacol Ther 119 2008 326 339
21. D.A. Saint The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 153 2008 1133 1142
22. P.B. Bennett, K. Yazawa, N. Makita, and A.L. George Jr Molecular mechanism for an inherited cardiac arrhythmia Nature 376 1995 683 685
23. D.S. Echt, P.R. Liebson, L.B. Mitchell the CAST Investigators Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial N Engl J Med 324 1991 781 788
24. A. Pezhouman, S. Madahian, H. Stepanyan, H. Ghukasyan, Z. Qu, L. Belardinelli, and H.S. Karagueuzian Selective inhibition of late sodium current suppresses ventricular tachycardia and fibrillation in intact rat hearts Heart Rhythm 11 2014 492 501
25. S.M. Narayan, M.R. Franz, P. Clopton, E.J. Pruvot, and D.E. Krummen Repolarization alternans reveals vulnerability to human atrial fibrillation Circulation 123 2011 2922 2930
26. F.T.J. Jousset, J.M. Vesin, P. Pascale, P. Ruchat, A. Garderes Rollin, M. Fromer, S.M. Narayan, and E. Pruvot Kinetics of atrial repolarization alternans in a free-behaving ovine model J Cardiovasc Electrophysiol 23 2012 1003 1012
27. P. Comtois, and S. Nattel Atrial repolarization alternans as a path to atrial fibrillation [editorial] J Cardiovasc Electrophysiol 23 2012 1013 1015
28. J.N. Weiss, A. Karma, Y. Shiferaw, P.S. Chen, A. Garfinkel, and Z. Qu From pulsus to pulseless: the saga of cardiac alternans Circ Res 98 2006 1244 1253
29. R.L. Verrier, and T. Nieminen T-wave alternans as a therapeutic marker for antiarrhythmic agents J Cardiovasc Pharmacol 55 2010 544 554
30. S. Sicouri, L. Belardinelli, and C. Antzelevitch Antiarrhythmic effects of the highly selective late sodium channel current blocker GS-458967 Heart Rhythm 10 2013 1036 1043
31. E.N. Moore, and J.F. Spear Ventricular fibrillation threshold: its physiological and pharmacological importance Arch Intern Med 135 1975 446 453
32. S.C. Krishnan, and C. Antzelevitch Flecainide-induced arrhythmia in canine ventricular epicardium: phase 2 reentry? Circulation 87 1993 562 572
33. Ks participation in cardiac repolarization and repolarization reserve Circulation 112 2005 1384 1391
34. M.C. Wijffels, C.J. Kirchhof, R. Dorland, and M.A. Allessie Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats Circulation 92 1995 1954 1968
35. K. Kumar, B.D. Nearing, C.R. Bartoli, K.F. Kwaku, L. Belardinelli, and R.L. Verrier Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart J Cardiovasc Electrophysiol 19 2008 1073 1079
36. K. Kumar, B.D. Nearing, M. Carvas, B.C.G. Nascimento, M. Acar, L. Belardinelli, and R.L. Verrier Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart J Cardiovasc Electrophysiol 20 2009 796 802
37. + channels by ranolazine, I: experimental analysis of the use-dependent block Am J Physiol Heart Circ Physiol 301 2011 H1606 H1614